Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Assistance Publique - Hôpitaux de Paris
With
URC-CIC Paris Descartes Necker Cochin
The study is divided in 4 parts:
Part 1: study of cellular infiltrate (lymphocytes) performed on large primary melanoma and cutaneous metastasis ( fresh samples) Part 2: NK cells study on metastatic regional lymph nodes ( fresh samples) and blood samples Part 3: a retrospective study of macrophages in sentinel lymph nodes and in corresponding primary melanomas Part 4: study of the cellular modulation by the chemotherapy (DTIC or cisplatin or inhibitor of B-raf) which(who) will be made on two cutaneous metastases by patient (one taken before the treatment(processing) and one taken during the evaluation after 2 or 3 cycles of treatment(processing))
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with confirmed melanoma-patients informed of the aims of the study , the modalities
Patients who signed the consent form ou a non opposition form signed by the patient or by a relative
According to study part:
Part 1: patients with a melanoma larger than 10mm or with cutaneous metastasis Part 2: stage IV melanoma patients who shall undergo a regional lymph node dissection Part 3: retrospective study of patients who underwent a sentinel node procedure Part 4: Patients achieves of inoperable melanomas the stage(stadium) III or IV that must receive in treatment (processing) a chemotherapy (by the dacarbazine or by the cisplatin or by the inhibitor of B-raf) and carrier of at least two cutaneous metastases
You may not be if
Refusal to take part in the study (patient or relative)
Contraindications known to the xylocaine (groups 1,2, and 4)
No affiliated to the social security system (groups 1, 2, and 4)
Clareo Health | Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients
